EP Patent

EP3320904B1 — Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure

Assigned to Santen Pharmaceutical Co Ltd · Expires 2023-07-05 · 3y expired

What this patent protects

Patent listed against omidenepag-isopropyl.

Drugs covered by this patent

omidenepag-isopropyl (OMIDENEPAG ISOPROPYL)

Patent Metadata

Patent number: EP3320904B1
Jurisdiction: EP
Classification: —
Expires: 2023-07-05
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.